NeurAxis Reports 80% Revenue Growth in Q1 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 56 minutes ago
0mins
Should l Buy NRXS?
Source: Newsfilter
- Significant Revenue Growth: NeurAxis reported revenues of $1.6 million for Q1 2026, an 80% increase year-over-year, primarily driven by the effective AMA Category I CPT® code on January 1, 2026, which substantially enhanced payer coverage and boosted sales.
- Gross Margin Improvement: The gross margin increased from 84.4% in Q1 2025 to 86.4% in Q1 2026, primarily due to a higher volume of IB-Stim® devices sold at full price, reflecting the company's strengthened competitive position in the market.
- Reduced Operating Loss: The operating loss for Q1 2026 decreased by 24% to $1.74 million, mainly due to increased gross profit from revenue growth, despite a slight rise in operating expenses driven by sales growth, indicating progress in cost control.
- Improved Cash Position: As of March 31, 2026, NeurAxis had a cash balance of $7.1 million, and subsequently raised $2.1 million through market offerings and warrant exercises in April and May 2026, further enhancing the company's liquidity and financial stability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NRXS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NRXS
Wall Street analysts forecast NRXS stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.200
Low
8.00
Averages
8.00
High
8.00
Current: 8.200
Low
8.00
Averages
8.00
High
8.00
About NRXS
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. Its IB-Stim, is a Percutaneous Electrical Nerve Field Stimulation (PENFS) technology intended to be used in patients eight years and older with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. Its second product, RED (Rectal Expulsion Device), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge to defecate at lower volumes of distension.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NeurAxis Reports 80% Revenue Growth in Q1 2026
- Significant Revenue Growth: NeurAxis reported revenues of $1.6 million for Q1 2026, an 80% increase year-over-year, primarily driven by the effective AMA Category I CPT® code on January 1, 2026, which substantially enhanced payer coverage and boosted sales.
- Gross Margin Improvement: The gross margin increased from 84.4% in Q1 2025 to 86.4% in Q1 2026, primarily due to a higher volume of IB-Stim® devices sold at full price, reflecting the company's strengthened competitive position in the market.
- Reduced Operating Loss: The operating loss for Q1 2026 decreased by 24% to $1.74 million, mainly due to increased gross profit from revenue growth, despite a slight rise in operating expenses driven by sales growth, indicating progress in cost control.
- Improved Cash Position: As of March 31, 2026, NeurAxis had a cash balance of $7.1 million, and subsequently raised $2.1 million through market offerings and warrant exercises in April and May 2026, further enhancing the company's liquidity and financial stability.
See More
NeurAxis Declares Dividend on Series B Preferred Stock
- Dividend Announcement: On April 10, 2026, NeurAxis announced a stock dividend for holders of Series B Preferred Stock, requiring record holders by April 21, 2026, which demonstrates the company's commitment to shareholder returns.
- Dividend Details: Each holder of Series B Preferred Stock will receive common stock based on accrued unpaid dividends at a rate of $2.38, with approximately 510,605 shares expected to be issued, enhancing the company's capital structure flexibility.
- Cash Alternative: For any fractional shares that cannot be issued, NeurAxis will compensate in cash, ensuring all shareholders receive corresponding value, reflecting the company's commitment to shareholder rights.
- Future Outlook: The dividend announcement not only indicates the company's stable financial condition but may also attract more investor interest, further boosting market confidence and potentially enhancing stock performance.
See More
Neuraxis Inc Reports Q4 2025 Earnings with Mixed Results
- Significant Revenue Growth: Neuraxis Inc reported revenues of $968,000 for Q4 2025, a 27% increase from $761,000 in Q4 2024, marking the sixth consecutive quarter of double-digit growth, indicating strong market expansion potential.
- Gross Margin Decline: Despite revenue growth, the gross margin for Q4 decreased to 85.4% from 86.4% in Q4 2024, primarily due to reserves for excess and obsolete inventory, which may impact future profitability.
- Increased Net Loss: The company reported a net loss of $1.7 million for Q4 2025, an 18% increase compared to the same period in 2024, reflecting rising operating expenses of $2.5 million, highlighting challenges in cost control.
- Strong Cash Flow Position: Neuraxis Inc ended 2025 with $5 million in cash on hand and a free cash flow of $2 million, exceeding the quarterly burn rate of $1.5 million, demonstrating robust financial management.
See More
NeurAxis Reports Q4 2025 Financial Results
- Increased Net Loss: NeurAxis reported a net loss of $1.7 million in Q4 2025, an 18% increase from $1.4 million in Q4 2024, primarily due to higher operating losses, indicating challenges in cost management.
- Revenue Performance: The revenue for the quarter stood at $0.97 million; while specific growth figures were not disclosed, the revenue level suggests insufficient competitiveness in the market, potentially impacting future financing capabilities.
- Impact of Operating Loss: The increase in operating losses puts pressure on NeurAxis's financial condition, which may lead to decreased investor confidence in the company's future profitability, thereby affecting stock performance.
- Market Reaction Expectations: Following the earnings report, market reactions to NeurAxis may lean negative, prompting investors to closely monitor how the company addresses ongoing financial challenges and its future strategic adjustments.
See More
Meta Platforms Sees 3.6% Stock Growth Driven by User Engagement
- User Growth: Meta Platforms has experienced steady user growth over the past year, particularly in the Asia-Pacific region, leading to a 3.6% stock increase, outperforming the 1.1% growth of the Internet - Software industry, which enhances its competitive position.
- AI Application: By leveraging artificial intelligence to improve the effectiveness of its platform services, Meta now reaches over 3.54 billion daily users, boosting its appeal to advertisers and is expected to drive future revenue growth.
- Investment Plans: Meta plans to significantly increase investments in advanced AI models over the next few years, although the monetization of these AI services may take considerable time, posing challenges to the company's future profitability.
- Market Performance: While Meta's stock performance has been strong, attention must be paid to its competitive edge in the advertising market and the monetization of AI services to ensure sustained growth and investor confidence.
See More
NeurAxis Secures Major Medical Policy Coverage for PENFS, Impacting 45 Million Members
- Policy Coverage Expansion: NeurAxis announced that its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, has received medical policy coverage from a major national health insurer, impacting approximately 45 million health plan members and significantly enhancing the therapy's market recognition.
- Unique Treatment Solution: IB-Stim is an FDA-cleared non-invasive device specifically designed for treating functional abdominal pain in patients aged 8 and older, addressing a significant unmet medical need in pediatric functional dyspepsia treatment.
- Revenue Growth Potential: With the implementation of a Category I CPT code effective January 1, 2026, NeurAxis is positioned for substantial revenue growth and margin expansion, further solidifying its leadership in the medical technology sector.
- Increased Clinical Recognition: The company is aggressively working to secure additional coverage from large national insurers, indicating the growing recognition of IB-Stim as a necessary, evidence-based therapy for pediatric gastrointestinal disorders.
See More
NeurAxis Reports 80% Revenue Growth in Q1 2026
- Significant Revenue Growth: NeurAxis reported revenues of $1.6 million for Q1 2026, an 80% increase year-over-year, primarily driven by the effective AMA Category I CPT® code on January 1, 2026, which substantially enhanced payer coverage and boosted sales.
- Gross Margin Improvement: The gross margin increased from 84.4% in Q1 2025 to 86.4% in Q1 2026, primarily due to a higher volume of IB-Stim® devices sold at full price, reflecting the company's strengthened competitive position in the market.
- Reduced Operating Loss: The operating loss for Q1 2026 decreased by 24% to $1.74 million, mainly due to increased gross profit from revenue growth, despite a slight rise in operating expenses driven by sales growth, indicating progress in cost control.
- Improved Cash Position: As of March 31, 2026, NeurAxis had a cash balance of $7.1 million, and subsequently raised $2.1 million through market offerings and warrant exercises in April and May 2026, further enhancing the company's liquidity and financial stability.
See More
NeurAxis Declares Dividend on Series B Preferred Stock
- Dividend Announcement: On April 10, 2026, NeurAxis announced a stock dividend for holders of Series B Preferred Stock, requiring record holders by April 21, 2026, which demonstrates the company's commitment to shareholder returns.
- Dividend Details: Each holder of Series B Preferred Stock will receive common stock based on accrued unpaid dividends at a rate of $2.38, with approximately 510,605 shares expected to be issued, enhancing the company's capital structure flexibility.
- Cash Alternative: For any fractional shares that cannot be issued, NeurAxis will compensate in cash, ensuring all shareholders receive corresponding value, reflecting the company's commitment to shareholder rights.
- Future Outlook: The dividend announcement not only indicates the company's stable financial condition but may also attract more investor interest, further boosting market confidence and potentially enhancing stock performance.
See More
Neuraxis Inc Reports Q4 2025 Earnings with Mixed Results
- Significant Revenue Growth: Neuraxis Inc reported revenues of $968,000 for Q4 2025, a 27% increase from $761,000 in Q4 2024, marking the sixth consecutive quarter of double-digit growth, indicating strong market expansion potential.
- Gross Margin Decline: Despite revenue growth, the gross margin for Q4 decreased to 85.4% from 86.4% in Q4 2024, primarily due to reserves for excess and obsolete inventory, which may impact future profitability.
- Increased Net Loss: The company reported a net loss of $1.7 million for Q4 2025, an 18% increase compared to the same period in 2024, reflecting rising operating expenses of $2.5 million, highlighting challenges in cost control.
- Strong Cash Flow Position: Neuraxis Inc ended 2025 with $5 million in cash on hand and a free cash flow of $2 million, exceeding the quarterly burn rate of $1.5 million, demonstrating robust financial management.
See More
NeurAxis Reports Q4 2025 Financial Results
- Increased Net Loss: NeurAxis reported a net loss of $1.7 million in Q4 2025, an 18% increase from $1.4 million in Q4 2024, primarily due to higher operating losses, indicating challenges in cost management.
- Revenue Performance: The revenue for the quarter stood at $0.97 million; while specific growth figures were not disclosed, the revenue level suggests insufficient competitiveness in the market, potentially impacting future financing capabilities.
- Impact of Operating Loss: The increase in operating losses puts pressure on NeurAxis's financial condition, which may lead to decreased investor confidence in the company's future profitability, thereby affecting stock performance.
- Market Reaction Expectations: Following the earnings report, market reactions to NeurAxis may lean negative, prompting investors to closely monitor how the company addresses ongoing financial challenges and its future strategic adjustments.
See More
Meta Platforms Sees 3.6% Stock Growth Driven by User Engagement
- User Growth: Meta Platforms has experienced steady user growth over the past year, particularly in the Asia-Pacific region, leading to a 3.6% stock increase, outperforming the 1.1% growth of the Internet - Software industry, which enhances its competitive position.
- AI Application: By leveraging artificial intelligence to improve the effectiveness of its platform services, Meta now reaches over 3.54 billion daily users, boosting its appeal to advertisers and is expected to drive future revenue growth.
- Investment Plans: Meta plans to significantly increase investments in advanced AI models over the next few years, although the monetization of these AI services may take considerable time, posing challenges to the company's future profitability.
- Market Performance: While Meta's stock performance has been strong, attention must be paid to its competitive edge in the advertising market and the monetization of AI services to ensure sustained growth and investor confidence.
See More
NeurAxis Secures Major Medical Policy Coverage for PENFS, Impacting 45 Million Members
- Policy Coverage Expansion: NeurAxis announced that its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, has received medical policy coverage from a major national health insurer, impacting approximately 45 million health plan members and significantly enhancing the therapy's market recognition.
- Unique Treatment Solution: IB-Stim is an FDA-cleared non-invasive device specifically designed for treating functional abdominal pain in patients aged 8 and older, addressing a significant unmet medical need in pediatric functional dyspepsia treatment.
- Revenue Growth Potential: With the implementation of a Category I CPT code effective January 1, 2026, NeurAxis is positioned for substantial revenue growth and margin expansion, further solidifying its leadership in the medical technology sector.
- Increased Clinical Recognition: The company is aggressively working to secure additional coverage from large national insurers, indicating the growing recognition of IB-Stim as a necessary, evidence-based therapy for pediatric gastrointestinal disorders.
See More
